Latest News

Blinatumomab Improves Outcomes in B-Cell Acute Lymphoblastic Leukemia
Blinatumomab Improves Outcomes in B-Cell Acute Lymphoblastic Leukemia

July 1st 2024

Blinatumomab integration led to high complete response and minimal residual disease-negativity rates, especially in patients over 40 and Philadelphia chromosome-positive cases.

FDA Expands Blinatumomab Approval Early-Stage CD19+ B-ALL
FDA Expands Blinatumomab Approval Early-Stage CD19+ B-ALL

June 14th 2024

Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL

April 22nd 2024

FDA Considers SH-201 for Treating Certain Leukemias and Cancers
FDA Considers SH-201 for Treating Certain Leukemias and Cancers

April 8th 2024

Revumenib Shows Efficacy/Safety in Pediatric and Adult R/R KMT2Ar AML/ALL
Revumenib Shows Efficacy/Safety in Pediatric and Adult R/R KMT2Ar AML/ALL

April 8th 2024

Video Series
Video Interviews

More News